Mckesson Corp

Company facts

Industry

Wholesale-Drugs, Proprietaries & Druggists' Sundries

Headquarters

Irving, Texas

Most recent report

8-K, filed Aug 28, 2026

Incorporated

Delaware

Filings on record

1,001+ filings

On EDGAR

CIK 927653

Fiscal year ends

March

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 2 of 13 sections worth reading, with 4 positive, 3 notable, and 4 negative flags.

• Financial Statements (Item 1)

  Full financials; revenue up 8% but net income down 22% on noncontrolling interest adjustments.
  Positive

  • Quarterly dividend raised from $0.82 to $0.94 per share, announced July 21, 2026.
  • Board authorized an additional $5.0B in share repurchases in April 2026.
  Notable

  • New multi-year restructuring programs approved with expected total charges of $230M-$310M.

• Management's Discussion (Item 2)

  Essential first look at Q1: revenue up 8% but net income down 22%, debt ratio spikes to 156%, massive buyback.
  Positive

  • Revenue up 8% to $105.4B, growth across North American Pharma and Oncology segments.
  • Returned $2.6B to shareholders via $2.5B buybacks and $102M dividends; new $5B buyback authorization added.
  Notable

  • Noncontrolling interest remeasurements added $293M (Med-Surg) and $81M (Core Ventures) charges.
  • $5.7B total estimated litigation liability for opioid-related claims remains outstanding.
  Negative

  • Restructuring charges jumped to $136M from $47M a year ago, with new multi-year programs.
  • Interest expense rose 57% to $77M due to higher average loan balances from new Med-Surg debt.
  • Net income attributable to McKesson fell 22% to $614M; diluted EPS dropped 18% to $5.15.
  • Operating cash flow negative $220M, though improved from $(918)M last year, hurt by $701M higher tax payments.

What changed: Jun 2026 vs. Dec 2025

About 17% of MCK's Jun 2026 10-Q is new information. 75 paragraphs were added, 187 changed, and 174 removed. Below are the most important lines SECSift identified.

• Item 1 132
• Item 2 88
• Item 6 4
• Item 3 1
• Item 4 1
• Item 1A 1